Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Supernus Pharmaceuticals Prices Its IPO In The Range Of $12-$14 Per Share

Supernus Pharmaceuticals Wednesday announced that it has filed Form S-1 with the Securities and Exchange Commission or the SEC revealing the pricing of its initial public offering for 5,769,000 shares of common stock.

The company revealed that it anticipates to price the initial public offering to be between $12.00 and $14.00 per share of common stock.

The company further added that it has granted the underwriters an option to purchase up to 865,350 additional shares of common stock to cover over-allotments.

The company stated that itsd shares would be listed on the Nasdaq Global Market under the symbol "SUPN."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The U.K. economy grew more than estimated in the second quarter and the current account deficit widened from the first quarter, the Office for National Statistics said Tuesday. Gross domestic product grew 0.9 percent sequentially, up from the prior estimate of 0.8 percent. The annual growth was confirmed at 3.2 percent. Eurozone inflation slowed in September, as expected, to the lowest since late 2009 and the unemployment rate remained stable at a double digit level in August putting pressure on the European Central Bank to launch a full-blown easing. Inflation came in at 0.3 percent, slower than August's 0.4 percent. This was the lowest since October 2009, when prices fell 0.1 percent. Chinese authorities on Tuesday eased some rules for mortgages for buying a second home, in a bid to boost the housing market. The People's Bank of China and the China Banking Regulatory Commission said in a joint statement that buyers who already own one apartment, but have paid off the mortgage...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.